Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Phase 1 Completed 19 enrolled M.D. Anderson Cancer Center Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer.

Timeline

Start: 2008-02
Primary completion: 2015-01
Completion: —

Publications

Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 2010 Sep;7(9):494-509. doi: 10.1038/nrurol.2010.134.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	12.5 mg	Oral
Background	Bicalutamide	Other / unclassified	—	Oral
Background	Goserelin	Other / unclassified	—	Subcutaneous
Background	Leuprolide	Other / unclassified	—	Intramuscular

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications